FIGURE 2.

KS18 inhibits Mcl-1 at both transcriptional and post-translational levels. (A), U266 MM cells were treated with or without the indicated doses of KS18 for 24 h (B), KS18 therapy suppresses the activation of the STAT3-Mcl-1 promoter. The ChIP experiment was conducted as outlined in the Materials and Methods section. GraphPad Prism was utilized for graphical representations and statistical analysis. All data were shown as mean ± standard error of measurement. (C–E), 5 μM of KS18 was applied to U266 MM cells at various time points. For section (A, C, D, E), subsequent to incubation, the cells were lysed and analyzed via immunoblotting as outlined in the Materials and Methods section, utilizing the specified antibodies. The GAPDH antibody functioned as a loading control. Cells treated with vehicles served as the control. ****P ≤ 0.0001.